Almost all cases of APL are defined at the molecular level by the presence of a balanced reciprocal translocation t(15;17) resulting in the PML-RARa fusion gene [1] . APL is the most curable subtype of AML [2, 3] . With current therapy, including all trans retinoic acid (ATRA) and anthracycline-based chemotherapy, 70%-80% of patients are free of disease at 5 years [2, 3] .
Extramedullary disease in APL may occur at relapse, but it is a very rare clinical event at diagnosis, with half of the reported cases involving the skin [4, 5] . Other sites involve the central nervous system, gingival, lymph nodes and spleen. To our knowledge this is the first report of pleural tumors as sole extramedullary manifestation of APL at diagnosis. Our case indicates that determination of t(15;17) should be included in the panel of markers assessed at diagnosis of all AML patients, including patients with exclusively extramedullary AML. This also allows timely diagnosis of APL at unusual clinical presentation and thus possibly live-saving therapy with ATRA. 
